• Overall response (complete and partial) during first 24 weeks of treatment [ Designated as safety issue: No ]
  

• Time to progression [ Designated as safety issue: No ]
  
• Overall survival [ Designated as safety issue: No ]
  
• Progression-free survival [ Designated as safety issue: No ]
  
• Duration of response [ Designated as safety issue: No ]
  

OBJECTIVES:

• Determine the objective responses in patients with previously treated mantle cell non-Hodgkin's lymphoma treated with CCI-779.
• Determine the toxic effects of this drug in these patients.
• Determine whether this drug inhibits cell proliferation pathways in these patients.

OUTLINE: Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with stable disease receive a maximum of 6 courses. Patients with partial response receive a maximum of 12 courses. Patients with complete response (CR) receive 2 additional courses beyond CR.

Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually for 2 years.

PROJECTED ACCRUAL: A maximum of 27 patients will be accrued for this study within 2 years.

DISEASE CHARACTERISTICS:

• Histologically confirmed mantle cell non-Hodgkin's lymphoma (MCL)
• Relapsed, refractory, or stable disease after prior chemotherapy, radiotherapy, or immunotherapy

• Unidimensionally measurable lymph node or lesion

  • At least 2.0 cm by CT scan or MRI OR at least 1.5 cm by physical exam

  • One of the following measurement parameters may be used:

    • Splenic enlargement may be used as a measurement parameter if spleen is palpable at least 3.0 cm across left costal margin
    • Malignant lymphocytosis may be used as a measurement parameter if absolute lymphocyte count is at least 5,000/mm^3
• No known CNS involvement (parenchymal mass or leptomeningeal involvement)

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• ECOG 0-2

Life expectancy:

• At least 3 months

Hematopoietic:

• See Disease Characteristics
• Absolute neutrophil count ≥ 1,000/mm^3
• Platelet count ≥ 75,000/mm^3
• Hemoglobin ≥ 8 g/dL

Hepatic:

• Total bilirubin ≤ 1.5 times upper limit of normal (ULN) OR
• Direct bilirubin ≤ 1.5 times ULN
• AST ≤ 3 times ULN (5 times ULN if liver metastases are present)

Renal:

• Creatinine ≤ 2 times ULN

Cardiovascular:

• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia

Other:

• Cholesterol ≤ 350 mg/dL
• Triglycerides ≤ 400 mg/dL
• HIV negative
• No other active malignancy requiring treatment or that would preclude study participation
• No other concurrent uncontrolled illness
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study participation
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• See Disease Characteristics
• Prior high-dose therapy with stem cell transplantation allowed
• At least 7 days since prior immunotherapy or other non-myelosuppressive biologic response modifiers

Chemotherapy:

• See Disease Characteristics
• See Biologic therapy
• At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas or mitomycin)
• No other concurrent chemotherapy for MCL

Endocrine therapy:

• Concurrent corticosteroids for adrenal insufficiency allowed

Radiotherapy:

• See Disease Characteristics
• At least 3 weeks since prior radiotherapy
• No concurrent radiotherapy for MCL

Surgery:

• Not specified

Other:

• Any number of prior treatments allowed
• No other concurrent investigational or commercial agents for MCL
• No concurrent drugs that induce cytochrome p450 (e.g., carbamazepine, phenobarbital, phenytoin, ketoconazole, diltiazem, rifampin, terfenadine, cisapride, astemizole, or pimozide)
• No concurrent immunosuppressive therapies